You are currently viewing Rejuvenate Bio and Merck Animal Health Partner on Companion Animal Gene Therapy 

Rejuvenate Bio and Merck Animal Health Partner on Companion Animal Gene Therapy 

Rejuvenate Bio and Merck Animal Health have entered a strategic research and development collaboration to advance a novel gene therapy program for companion animals, BioPharma APAC reported in June 2026. The partnership was announced alongside Rejuvenate Bio’s $6 million financing round, led by VCapital with Merck Animal Health participating. 

Investor Lifespan Vision Ventures described Merck Animal Health’s dual role as investor and collaborator as a vote of confidence in the company’s team and science. 

Inside the Rejuvenate Bio and Merck Animal Health Collaboration 

The collaboration will draw on Rejuvenate Bio’s proprietary platform technologies and translational expertise to develop next-generation treatments for chronic disease in companion animals. Financing proceeds will support the company’s gene therapy platform and pipeline, including programs for chronic and age-associated conditions in pets. 

Rejuvenate’s approach is liver-directed gene therapy that does not edit the genome. A single administration is designed to enable the body to produce therapeutic proteins on its own, rather than relying on repeated dosing. 

Building on Earlier Animal Health Partnerships 

Merck Animal Health is not Rejuvenate’s first industry partner. Phibro Animal Health signed on in 2022 to develop and commercialize a gene therapy for mitral valve disease in dogs, and Rejuvenate has since identified Merck Animal Health as its partner on a canine osteoarthritis program announced in 2024. 

About Rejuvenate Bio 

Rejuvenate Bio is a San Diego gene therapy company built on research from George Church’s lab at Harvard Medical School. Jetstream Venture Fund invested in the company in June 2026, the same month the financing closed. 

Frequently Asked Questions 

What will Rejuvenate Bio and Merck Animal Health develop together? 

The companies will advance a novel gene therapy program in animal health using Rejuvenate Bio’s proprietary platform and translational expertise. The collaboration focuses on next-generation treatments for chronic diseases in companion animals such as dogs. 

Who invested in Rejuvenate Bio’s $6 million round? 

VCapital led Rejuvenate Bio’s $6 million financing, announced in June 2026. Merck Animal Health, Kendall Capital Partners, Connecticut Innovations, and Digitalis also participated, with proceeds supporting the company’s gene therapy platform and companion animal pipeline. 

Read the Original Article: Rejuvenate Bio and Merck Animal Health Join Forces on Novel Animal Health Gene Therapy Programme